B022 NEW
| Price | $68 | $168 | $247 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: B022 | CAS No.: 1202764-53-1 |
| Purity: 99.74% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | B022 |
| Description | B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins. |
| In vitro | B022 treatment of Hepa1 cells (0 μM, 0.5 μM, 5 μM; 12 hours) can suppress NIK-induced p52 formation in a dose-dependent manner[1]. |
| In vivo | In STOP-NIK male mice (8 weeks old) infected with Ad-cre, B022 (30 mg/kg; intravenous injection; twice daily; for 10 days) completely prevents the lethal effects induced by abnormally high levels of hepatic NIK in mice. It inhibits the majority of the deteriorating effects caused by aberrant activation of hepatic NIK[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 200 mg/mL (502.66 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.57 mM), Sonication is recommended. |
| Keywords | NIK | NF-κB-inducing kinase NIK | NFκB | NF-kB | NFkB | B-022 | B022 | B 022 |
| Inhibitors Related | Sodium Houttuyfonate | Zingerone | Lidocaine | α-Lipoic Acid | Diethylmaleate | Glucosamine | sodium lauroyl-α-hydroxyethyl sulfonate | Lidocaine hydrochloride | 5-Aminosalicylic Acid | Indole-3-carbinol | Diallyl disulfide | Sodium salicylate |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | NF-κB Signaling Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $68.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-11-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY